{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:25:03Z","timestamp":1775287503311,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.vaccine.2016.12.067","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T11:01:12Z","timestamp":1483700472000},"page":"716-721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Could the RTS,S\/AS01 meningitis safety signal really be a protective effect of rabies vaccine?"],"prefix":"10.1016","volume":"35","author":[{"given":"Bradford D.","family":"Gessner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darryn L.","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Conan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.067_b0005","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31\u201345.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"10.1016\/j.vaccine.2016.12.067_b0010","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(16)30081-2","article-title":"CNS infection safety signal of RTS,S\/AS01 and possible association with rabies vaccine","volume":"387","author":"Gessner","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.12.067_b0015","first-page":"810","article-title":"Estimating meningitis hospitalization rates for sentinel hospitals conducting invasive bacterial vaccine-preventable diseases surveillance","volume":"62","author":"Centers for Disease C, Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.12.067_b0020","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1093\/cid\/ciu057","article-title":"Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and Haemophilus influenzae type b vaccination, 2000\u20132012","volume":"58","author":"Wall","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.067_b0025","doi-asserted-by":"crossref","first-page":"e52464","DOI":"10.1371\/journal.pone.0052464","article-title":"Pneumococci in the African meningitis belt: meningitis incidence and carriage prevalence in children and adults","volume":"7","author":"Mueller","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.067_b0030","unstructured":"Smith P on behalf of the Joint Technical Expert Group (JTEG). JTEG\u2019s summary of RTS,S\/AS01 clinical trial data. <http:\/\/www.who.int\/immunization\/sage\/meetings\/2015\/october\/presentations_background_docs\/en\/>; 2015 (accessed 22 November 2015)."},{"key":"10.1016\/j.vaccine.2016.12.067_b0035","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/jama.293.12.1461","article-title":"Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria","volume":"293","author":"Reyburn","year":"2005","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.12.067_b0040","first-page":"7","article-title":"Severe malaria","volume":"19","author":"World Health Organization","year":"2014","journal-title":"Trop Med Internat Health"},{"key":"10.1016\/j.vaccine.2016.12.067_b0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-3156.2008.02076.x","article-title":"Estimates of the burden of malaria morbidity in Africa in children under the age of 5 years","volume":"13","author":"Roca-Feltrer","year":"2008","journal-title":"Trop Med Internat Health"},{"key":"10.1016\/j.vaccine.2016.12.067_b0050","doi-asserted-by":"crossref","first-page":"e79323","DOI":"10.1371\/journal.pone.0079323","article-title":"Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial","volume":"8","author":"Laurens","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.067_b0055","doi-asserted-by":"crossref","first-page":"e14090","DOI":"10.1371\/journal.pone.0014090","article-title":"Safety of the malaria vaccine candidate, RTS,S\/AS01E in 5 to 17 month old Kenyan and Tanzanian Children","volume":"5","author":"Lusingu","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.067_b0060","doi-asserted-by":"crossref","first-page":"e7302","DOI":"10.1371\/journal.pone.0007302","article-title":"Randomized controlled trial of RTS,S\/AS02D and RTS,S\/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children","volume":"4","author":"Owusu-Agyei","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.067_b0065","doi-asserted-by":"crossref","first-page":"e6465","DOI":"10.1371\/journal.pone.0006465","article-title":"Evaluation of RTS,S\/AS02A and RTS,S\/AS01B in adults in a high malaria transmission area","volume":"4","author":"Polhemus","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.067_b0070","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1371\/journal.pone.0000707","article-title":"Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"2","author":"Bejon","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.067_b0075","doi-asserted-by":"crossref","first-page":"e4708","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"Ogutu","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.067_b0080","first-page":"269","article-title":"Evidence for a non-specific immunostimulating effect on anti-rabies vaccine of the Fermi type on the Klebsiella pneumoniae system \u2013 mice","volume":"48","author":"Brossat","year":"1981","journal-title":"Arch Inst Pasteur Madagascar"},{"key":"10.1016\/j.vaccine.2016.12.067_b0085","doi-asserted-by":"crossref","first-page":"e0004177","DOI":"10.1371\/journal.pntd.0004177","article-title":"Population dynamics of owned, free-roaming dogs: implications for rabies control","volume":"9","author":"Conan","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.12.067_b0090","first-page":"610","article-title":"Non-specific defense reactions in the central nervous system following antirabies vaccination","volume":"15","author":"Gorshunova","year":"1970","journal-title":"Vopr Virusol"},{"key":"10.1016\/j.vaccine.2016.12.067_b0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/joim.12391","article-title":"A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009\u20132010 Pandemrix vaccination programme in Sweden","volume":"278","author":"Feltelius","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2016.12.067_b0100","doi-asserted-by":"crossref","first-page":"294ra105","DOI":"10.1126\/scitranslmed.aab2354","article-title":"Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2","volume":"7","author":"Ahmed","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.12.067_b0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2010.07.003","article-title":"'ASIA' \u2013 autoimmune\/inflammatory syndrome induced by adjuvants","volume":"36","author":"Shoenfeld","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2016.12.067_b0110","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3201\/eid1301.060810","article-title":"Rabies encephalitis in malaria-endemic area, Malawi, Africa","volume":"13","author":"Mallewa","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.067_b0115","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(03)13771-3","article-title":"Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies","volume":"361","author":"Aaby","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.12.067_b0120","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.38261.496366.82","article-title":"Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso","volume":"329","author":"Vaugelade","year":"2004","journal-title":"Brit Med J"},{"key":"10.1016\/j.vaccine.2016.12.067_b0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/cit692","article-title":"Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later","volume":"58","author":"Hoschler","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.067_b0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbiomolbio.2015.02.007","article-title":"Strategies to interfere with PDZ-mediated interactions in neurons: what we can learn from the rabies virus","volume":"119","author":"Caillet-Saguy","year":"2015","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.vaccine.2016.12.067_b0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/358507a0","article-title":"Evidence for a viral superantigen in humans","volume":"358","author":"Lafon","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.12.067_b0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0923-2494(93)80121-E","article-title":"Rabies virus superantigen","volume":"144","author":"Lafon","year":"1993","journal-title":"Res Immunol"},{"key":"10.1016\/j.vaccine.2016.12.067_b0145","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.183.4.1623","article-title":"Rabies superantigen as a Vbeta T-dependent adjuvant","volume":"183","author":"Astoul","year":"1996","journal-title":"J Experiment Med"},{"key":"10.1016\/j.vaccine.2016.12.067_b0150","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0264-410X(98)00357-0","article-title":"Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine?","volume":"17","author":"Drings","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.067_b0155","unstructured":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 \u2013 conclusions and recommendations. Wkly Epidemiol Rec 2015;90:681\u201399."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17300014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17300014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T08:23:03Z","timestamp":1536135783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17300014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0264410X17300014"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could the RTS,S\/AS01 meningitis safety signal really be a protective effect of rabies vaccine?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}